Capsul Desk

Capsul Desk writes each daily edition. We are senior reporters and editors from Norstella's News and Insights division, with decades covering the industry's full arc, from a molecule's first trial to the pricing fight that decides who can afford it.

Page 1 of 4

Sunlit Madrid street with traffic, period buildings and a domed landmark under scaffolding.

Milestone Monday: Out With A Stake, In With A Franchise: RedHill's Two-Day Reshuffle

Sep 7, 2026 Capsul Desk 4 min read members

An empty white built-in shelf with an aluminum folding ladder leaning against it.

The Long View: The Doctor Who Keeps Choosing The Bare Cupboard

Sep 4, 2026 Capsul Desk 5 min read members

Secondhand books and records in cardboard boxes below a rack of used clothing at a street flea market.

Milestone Monday: Paying Up For The Sure Thing

Aug 31, 2026 Capsul Desk 6 min read members

A masked gardener carries a tree seedling, a spade, and a pot of soil through tall yellow wildflowers under an overcast sky.

The Long View: Big Pharma Is Growing Its Own Again

Aug 28, 2026 Capsul Desk 7 min read members

Tall stacks of thick paper case files bristling with tab markers on an office desk.

Milestone Monday: Count the Events, Not the Paperwork

Aug 24, 2026 Capsul Desk 5 min read members

People climbing an outdoor staircase in single file, seen from behind and below against a bright, washed-out sky.

Milestone Monday: In This IPO Market, $81m Is The Small One

Aug 17, 2026 Capsul Desk 4 min read members

The Long View: Sanofi Rebuilds Its Workforce Around AI, Just As It Gets Pickier About What Advances

The discovery engine now runs twice as fast. A new chief executive is culling late-stage assets and raising the Phase II bar, so the bet rides on whether faster also means better.

Aug 14, 2026 Capsul Desk 6 min read members

A sprinter crouched in the starting blocks on a red running track, one hand holding a relay baton behind the white start line, poised to push off.

Trial Tuesday: The Number Arrowhead Wasn't Looking For

Twin trials erased acute pancreatitis in high-risk patients, and Arrowhead priced its drug just above Ionis's, not below. The full readout lands at ESC on Aug 30, where analysts settle the score.

Aug 11, 2026 Capsul Desk 4 min read members